Pentostatin: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Pentostatin. Educational only — not medical advice.
Labeled uses
NIPENT is indicated as single-agent treatment for both untreated and alpha-interferon-refractory hairy cell leukemia patients with active disease as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms.
Source: FDA labeling via NIH DailyMed (set 674e0e6d…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.